NASDAQ:ANAB AnaptysBio Q2 2025 Earnings Results & Report $45.73 -0.52 (-1.12%) Closing price 04:00 PM EasternExtended Trading$47.28 +1.55 (+3.38%) As of 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. AnaptysBio beat analyst expectations on both earnings and revenue in its Q2 2025 results, released August 6, 2025. The company reported EPS of -$1.34 versus the -$1.50 consensus estimate, while revenue of $22.26 million topped the $11.55 million estimate by $10.71 million. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ2 2025Report DateAugust 6, 2025TimeBefore Market OpensConference Call4:00 PM ET AnaptysBio EPS ResultsActual EPS-$1.34Consensus EPS -$1.50Beat/MissBeat by +$0.16One Year Ago EPSN/AEPS Beat Rate7 of last 8 quartersAnaptysBio Revenue ResultsActual Revenue$22.26 millionExpected Revenue$11.55 millionBeat/MissBeat by +$10.71 millionYoY Revenue GrowthN/AConference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) AnaptysBio Q2 2025 Earnings FAQ Did AnaptysBio beat earnings estimates for Q2 2025? AnaptysBio (NASDAQ:ANAB) reported earnings of -$1.34 per share for Q2 2025, beating the consensus estimate of -$1.50. The report was announced on Wednesday, August 6, 2025. What was AnaptysBio's revenue for Q2 2025? AnaptysBio reported revenue of $22.26 million for Q2 2025, against a consensus estimate of $11.55 million. AnaptysBio Earnings HeadlinesAnaptysBio, Inc. Reports Earnings Results for the First Quarter Ended September 30, 2026November 12, 2026 | marketscreener.comMEarnings Flash (ANAB) AnaptysBio, Inc. Reports Q1 Revenue $30.3M, vs. FactSet Est of $18.9MNovember 12, 2026 | marketscreener.comM$0. Later: $29.97.Bill Poulos is giving away his Simple Options Trading For Beginners book through a temporary link. Once that link expires, it returns to its usual price of $29.97. The content stays the same - plain-English lessons and a handful of proven techniques - only the price changes. Waiting means paying for something you could have gotten for free.November 16 at 1:00 AM | Profits Run (Ad)Anaptys Reports Fiscal First Quarter 2027 Financial Results and Provides Business UpdateNovember 12, 2026 | globenewswire.comAnaptysBio, Inc. (ANAB) - What Are Analysts Thinking About This Stock?November 12, 2026 | americanbankingnews.comAnaptys Announces Participation in Upcoming Investor ConferencesNovember 10, 2026 | globenewswire.comSee More AnaptysBio Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like AnaptysBio? Sign up for Earnings360's daily newsletter to receive timely earnings updates on AnaptysBio and other key companies, straight to your email. Email Address About AnaptysBioAnaptysBio (NASDAQ:ANAB) is a biotechnology company focused on developing antibody-based treatments for inflammatory and autoimmune diseases. Its research programs target immune pathways that may be involved in conditions with significant unmet medical needs. The company’s pipeline has included rosnilimab, an investigational antibody designed to activate the PD-1 pathway, and ANB032, an investigational antibody targeting BTLA. AnaptysBio has also developed imsidolimab, an antibody targeting the IL-36 receptor; global rights to that program were licensed to Vanda Pharmaceuticals. Founded in 2005 and based in San Diego, California, AnaptysBio also has a history of licensing antibody-discovery programs to other pharmaceutical companies. Its work includes collaborations that have contributed to medicines developed and commercialized by partners.View AnaptysBio ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?3 Building-Materials Stocks Rallying While Homebuilders Struggle to Find BuyersMarketBeat Week in Review – 11/9 - 11/133 AI Hardware Leaders Are Raising Dividends, But Which Offers More Income?Nu Holdings Earnings Show a Compounder Priced Like a Brazil BetCould Big Buybacks Be the Next Catalyst for These 3 AI Stocks?Cerebras Q3 Results: How Much More Proof Does Wall Street Need? Upcoming Earnings Walt Disney (11/17/2026)Home Depot (11/17/2026)NVIDIA (11/17/2026)Lowe's Companies (11/18/2026)TJX Companies (11/18/2026)Target (11/18/2026)Palo Alto Networks (11/18/2026)NetEase (11/19/2026)Alibaba Group (11/19/2026)PDD (11/19/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.